Stepwise delivery of topiramate over prolonged period of time

• US 20050136108A1
• Filed: 08/18/2004
• Published: 06/23/2005
• Est. Priority Date: 08/22/2003
• Status: Abandoned Application

• Current Assignee: Clark P. Allphin, Noymi V. Yam, Padmaja Shivanand, Patrick S.L. Wong, Rhea Kimbel
• Original Assignee: Clark P. Allphin, Noymi V. Yam, Padmaja Shivanand, Patrick S.L. Wong, Rhea Kimbel
• Inventors: Yam, Noymi V., Wong, Patrick S.L., Shivanand, Padmaja, Kimbel, Rhea, Allphin, Clark P.
• Application Number:
  US10/920,934
• Publication Number:
  US 20050136108A1
• Time in Patent Office: Days
• US Class Current: 424/468
• CPC Class Codes: A61K 9/0004 Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants

Abstract

Compositions and dosage forms for enhanced dispersion of topiramate in a controlled release dosage form released from the dosage form as a dry or substantially dry erodible solid over a prolonged period of time at a stepwise increasing rate of release are described.

Claims

1. A controlled release dosage form comprising a compound, characterized by having a high dosage, low solubility and poor dissolution rate or a pharmaceutically acceptable acid addition salt thereof, a disintegrant and no surfactant adapted to release as an erodible solid over a prolonged period of time at a stepwise, increasing rate.

2. The dosage form of claim 1 wherein the compound is topiramate.

3. The dosage form of claim 1 wherein the prolonged period of time is six hours or greater.

4. The dosage form of claim 1 wherein the prolonged period of time is eight hours or greater.

5. The dosage form of claim 1 wherein the prolonged period of time is 10 hours or greater.

6. A bioerodible composition comprising a compound characterized by having a high dosage, low solubility and poor dissolution rate or a pharmaceutically acceptable acid addition salt thereof adapted to release the compound over a prolonged period of time at a stepwise, increasing rate of release with no surfactant.

7. The composition of claim 6 wherein the compound is topiramate.

8. The composition of claim 7 further comprising polyethylene oxide and polyvinylpyrrolidone.

9. The composition of claim 8 wherein the prolonged period of time is six hours or greater.

10. The composition of claim 6 further comprising a hydrophilic polymer carrier.

11. The composition of claim 6 further comprising a disintegrant.

12. The composition of claim 10 further comprising a disintegrant.

13. A method of treating a condition in a subject responsive to administration of a compound characterized by having a high dosage, low solubility and poor dissolution rate or a pharmaceutically acceptable acid addition salt thereof which comprises orally administering to the subject a dosage form adapted to release the compound at a stepwise increasing rate of release over a prolonged period of time with no surfactant.

14. The method of claim 13 wherein the compound is topiramate.

15. The method of claim 14 wherein the dosage form contains between 50 and 1200 mg of the compound.

16. The method of claim 15 wherein the dosage form comprises an osmotic material.

17. A dosage form comprising:

a) a wall defining a compartment, at least a portion of the wall being semipermeable;

b) an exit orifice formed or formable in the wall; and

c) an expandable layer located within the compartment remote from the exit orifice and in fluid communication with the semipermeable portion of the wall; and

d) a drug layer located within the compartment adjacent the exit orifice, the drug layer comprising a compound characterized by having a high dosage, low solubility and poor dissolution rate or a pharmaceutically acceptable acid addition salt thereof with no surfactant.

18. The dosage form of claim 17 wherein the compound is topiramate.

19. The dosage form of claim 17 further comprising a flow-promoting layer between the wall and the drug layer.

20. A method of treating a condition responsive to administration of a compound comprising administering to a subject a compound characterized by having a high dosage, low solubility and poor dissolution rate or a pharmaceutically acceptable acid addition salt thereof with no surfactant which comprises maintaining over a prolonged period of time a steady state concentration of compound in the plasma of a subject between 5 ng/ml and 2500 ng/ml, wherein the quotient formed from [C_max−

C_min]/C_avg is 3 or less.

21. The method of claim 20 wherein the compound is topiramate.

22. The method of claim 20 wherein the quotient is 2 or less.

23. The method of claim 20 wherein the quotient is 1 or less.

24. A controlled release oral dosage form of topiramate for once-a-day

administration to a subject comprising:

(a) A core comprising;

i. Topiramate;

ii. a structural polymer;

iii. a disintegrant;

iv. no surfactant;

(b) a semipermeable membrane at least partially surrounding the core; and

(c) an exit orifice through the semipermeable membrane which communicates with the core so as to allow release of the topiramate to the environment;

wherein the dosage form releases the topiramate over a prolonged period of time at a stepwise increasing rate of release.

25. The controlled release oral dosage form of claim 24 characterized by producing a substantially ascending blood plasma concentration of topiramate in the subject after a single dose over 24 hours.

26. A method for treating a condition responsive to topiramate comprising orally administering once a day to a subject a capsule shaped tablet core dosage form containing topiramate, a disintegrant and a pharmaceutically acceptable structural polymer carrier wherein the dosage form releases the topiramate at a substantially ascending release rate for a prolonged period of time.

27. A capsule shaped tablet dosage form comprising a drug composition containing topiramate, a structural polymer carrier and a disintegrant wherein the dosage form, following oral administration to a subject, releases the active agent from the dosage form at a substantially ascending release rate for a prolonged period of time.

28. The dosage form according to claim 27 comprising:

(a) a capsule shaped tablet core containing a plurality of layers wherein the drug composition is contained in at least one layer and at least one other layer comprises a suitable fluid-expandable polymer;

(b) a semipermeable membrane surrounding the capsule shaped tablet core to form a compartment having an osmotic gradient to drive fluid from an external fluid environment contacting the semipermeable membrane into the compartment; and

(c) an orifice formed through the semipermeable membrane and into the capsule shaped tablet core to permit topiramate to be released from within the compartment into the external fluid environment.

29. The dosage form according to claim 28, wherein the capsule shaped tablet core comprises three layers and a portion of the topiramate drug composition is contained within a first layer and the remaining portion of the topiramate drug composition is contained within a second layer, wherein the portion of topiramate contained within the first layer is less than the portion of topiramate contained within the second layer, and wherein the fluid-expandable polymer is contained within a third layer and the orifice is formed through the semipermeable membrane adjacent the first layer.

30. A method for treating a condition responsive to topiramate comprising administering once a day to a subject the capsule shaped tablet dosage form of claim 29.